Pmh11 a Swedish Pharmacoeconomic Evaluation of Escitalopram, a New Ssri: Comparison of Cost-Effectiveness Between Escitalopram, Citalopram, Fluoxetine and Venlafaxine

Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria

“…According to pharmaco-economic analyses, based on data from randomized, double-blind, trials or meta-analyses (Francois et al, 2003;Hemels et al, (Berto et al, 2000;Smit et al, 2006;Sobocki et al, 2006) have consistently found that indirect costs (i.e., loss of productivity) are much higher than direct costs (i.e., drug costs, outpatient care, hospitalizations, non-medical costs).…”

Do Productivity Costs Matter?

“…Ten studies [35,44,58,62,64,65,[69][70][71]74] used questionnaires to collect data on absenteeism, ten [33,34,39,42,51,57,60,61,68,92] used literature estimates, three [48][49][50] used estimates provided by medical professionals, one [63] used cost diaries, one [75] used data on doctors' certificates for absenteeism and five [40,41,66,72,73] did not specify the methods used to collect data on lost work time. Regarding the valuation of time lost from work, 13 studies [40,41,60,[62][63][64]66,[70][71][72][73]75,92] applied average (age/ sex dependent) wage and employment rates, five [49][50][51]61,68] used values based on GDP per capita,...…”

Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study

“…Thirdly, the study was not designed to measure the cost-effectiveness of escitalopram vs citalopram in MDD. Some previous studies demonstrated that escitalopram was significantly more effective than citalopram and was associated with lower health care costs (Demyttenaere et al 2005;Fantino et al 2007;Francois et al 2003;Wade et al 2005;Wu et al 2008). Further studies with varied dosage should be performed to compare the long-term efficiency, tolerability, and cost effectiveness between the two medicines.…”

“…In another randomized, double-blind, 24-week study, escitalopram 10 mg/d was not significantly more effective than citalopram 20 mg/d in long-term treatment (Colonna et al 2005). Compared with citalopram, escitalopram was associated with lower health care costs in some countries, particularly for the geriatric population (Demyttenaere et al 2005;Fantino et al 2007;Francois et al 2003;Wade et al 2005;Wu et al 2008).…”